2024Äê4ÔÂ2ÈÕ£¬ÉϺ£¸´µ©´óѧÁ¥ÊôÖÐɽҽԺ½éÈë¿ÆÁõÁèÏþ½ÌÊÚÍŶӣ¬ÍŽáca88ÉúÎïÔÚÖпÆÔººÍJCRÒ»ÇøÔÓÖ¾BMC Medicine£¨IF 9.3£©ÉϽÒÏþÁËÌâΪ“Blood leukocytes as a non-invasive diagnostic tool for thyroid nodules: a prospective cohort study”µÄÑо¿ÂÛÎÄ[1]¡£¸ÃÑо¿Êǹú¼ÊÉÏÊ׸ö½«ÍâÖÜѪ°×ϸ°ûDNA¼×»ù»¯ÊÖÒÕÓ¦ÓÃÓÚ¼××´ÏÙ½á½ÚÁ¼¶ñÐÔ¼ø±ðµÄÇ°Õ°ÐÔÐÐÁÐÑо¿£¬¿ª·¢ÁËÒ»ÖÖ¼××´ÏÙ½á½ÚÕï¶ÏÄ£×Ó£¨blood leukocyte DNA methylation model, BLDM£©£¬ÆäÌØÒì¶ÈºÍ׼ȷ¶ÈÓÅÓÚ³¬Éù£¬ÓÐÖúÓÚɸѡ³öÐè¾ÙÐлî¼ì¼ì²éµÄ»¼Õߣ¬´Ó¶ø×èÖ¹²»ÐëÒªµÄ´©´Ì»î¼ì£¬Ê¹¼××´ÏÙ½á½ÚµÄÕïÁƸüºÏÀíºÍ¸ßЧ¡£ca88ÉúÎï×÷ΪÏàÖúµ¥Î»£¬ÔÚ¼×»ù»¯ÉúÎï±ê¼ÇÎïµÄɸѡ¡¢Ä£×Ó¹¹½¨ºÍÑéÖ¤µÈ·½ÃæÌṩÁËÖ÷ÒªµÄÊÖÒÕÖ§³Ö¡£
ÎÄÕ½ÒÏþÔÚBMC MedicineÉÏ
¼××´ÏÙ½á½Ú£¨thyroid nodule, TN£©µÄ»¼²¡Âʸߴï49%[2]£¬ÔÚÕâЩ¼¼××´ÏÙ½á½ÚµÄÈËȺÖУ¬¼××´ÏÙ°©£¨thyroid cancer, TC£©Ô¼Õ¼7-15%[3]¡£¼××´ÏÙ½á½ÚÈËȺ½ÓÊܳ¬Éù¼ì²é£¬Êǽá½Ú¶ñÐÔΣº¦ÆÀ¹ÀµÄÖ÷ÒªÒ»²½£¬¸ÃÆÀ¹ÀÓÐÖúÓÚÈ·¶¨»¼ÕßÊÇ·ñÐèÒª¾ÙÐд©´Ì»î¼ì[4]¡£2017Ä꣬ÃÀ¹ú·ÅÉäѧ»á£¨ACR£©ÒýÈëÁ˼××´ÏÙ³ÉÏñ±¨¸æºÍÊý¾Ýϵͳ£¨TI-RADS£©[5]£¬¸ÃϵͳµÄʵÑéÓÐÖúÓÚÌá¸ß¼××´ÏÙ½á½ÚÕï¶Ï׼ȷÐÔ£¬µ«Ò»¸öÖ÷ÒªµÄÎÊÌâÈÔÈ»±£´æ£¬¾ÏµÍ³ÆÀ¹ÀÐè¾ÙÐÐ×éÖ¯»î¼ìµÄ»¼Õߣ¬Ô¼57.4%ÊÇÁ¼ÐÔ¼××´ÏÙ½á½Ú[6]£¬ÕâÒâζ×ÅÐí¶à»¼Õß½ÓÊÜÁ˲»ÐëÒªµÄ»î¼ì¼ì²é¡£
¿ª·¢Ò»ÖÖÇÖÈëÐÔ¸üС¡¢¸üÀû±ã¡¢¸ü׼ȷµÄÊÖÒÕ£¬ÔÚÏÖÓеij¬Éùɸ²éÕï¶ÏµÄ»ù´¡ÉÏÌá¸ß¼××´ÏÙ½á½ÚÕï¶ÏµÄÌØÒì¶ÈºÍ׼ȷ¶ÈÏÔµÃÓÈΪÖ÷Òª¡£±¾Ñо¿Á¢ÒìÐԵؽÓÄÉca88ÉúÎï×ÔÖ÷Ñз¢µÄ¼×»ù»¯µ¥±¶ÐÍÄ£¿é£¨MHB£©µÄÆÊÎöÒªÁ죬Àֳɿª·¢ÁËÒ»ÖÖ»ùÓÚÍâÖÜѪ°×ϸ°ûDNA¼×»ù»¯µÄ¼××´ÏÙ½á½ÚÕï¶ÏÄ£×Ó£¨BLDMÄ£×Ó£©£¬¸ÃÄ£×ÓÔÚÑéÖ¤¼¯ºÍ×ÔÁ¦²âÊÔ¼¯ÖеÄROCÇúÏßÏÂÃæ»ý£¨AUC£©»®·ÖµÖ´ï0.858ºÍ0.863£¬ÆäÌØÒì¶ÈÔÚÑéÖ¤¼¯ºÍ×ÔÁ¦²âÊÔ¼¯ÖÐΪ90.91%ºÍ88.68%£¬ÓÅÓÚ³¬Éù£¨ACR TI-RADS£©µÄÌØÒì¶È¡£ÌØÊâÔÚ¼××´ÏÙϸС½á½ÚÖУ¨≤10mm£©£¬¸ÃÄ£×ÓÏÔʾ³ö¸ü¸ßµÄÌØÒì¶È£¨ÑéÖ¤¼¯ÖÐΪ93.33%£¬×ÔÁ¦²âÊÔ¼¯ÖÐΪ92.00%£©ºÍ׼ȷ¶È£¨ÑéÖ¤¼¯ÖÐΪ88.24%£¬×ÔÁ¦²âÊÔ¼¯ÖÐΪ87.50%£©¡£ÔÚ³¬ÉùÏÓÒɶñÐÔ½á½Úµ«×éÖ¯²¡ÀíΪÁ¼ÐԵĻ¼ÕßÖУ¬BLDMÄ£×ÓµÄ׼ȷ¶ÈµÖ´ïÁË89.83%¡£Ñо¿Ð§¹û֤ʵ£¬BLDMÄ£×Ó¿ÉÒÔ×ÊÖú³¬ÉùÌá¸ß¼××´ÏÙ½á½ÚÕï¶ÏµÄÌØÒì¶ÈºÍ׼ȷ¶È£¬ÖúÁ¦½øÒ»²½É¸Ñ¡ÐèÐлî¼ì¼ì²éµÄ»¼Õß¡£
¡¸Ñо¿ÒªÁ졹
±¾Ñо¿¹²ÄÉÈë293·ÝѪҺÑù±¾£¨167·ÝÁ¼ÐÔ½á½Ú£¬126·Ý¶ñÐÔ½á½Ú)£¬Ñо¿Éè¼Æ¹²·ÖÈý¸ö½×¶Î£¬Èçͼ1Ëùʾ£º
µÚ¢ñ½×¶Î£¨É¸Ñ¡¼×»ù»¯±ê¼ÇÎ£ºÓ¦ÓÃRRBSÒªÁì¼ì²â59Ãûδ½ÓÊÜÖÎÁƵÄÁ¼ÐÔ½á½ÚºÍ49Ãû¶ñÐÔ½á½Ú»¼ÕßѪҺ°×ϸ°ûDNA£¬Ñ°ÕÒ²î±ð»¯¼×»ù»¯±ê¼ÇÎï¡£
µÚ¢ò½×¶Î£¨¿ª·¢ºÍÑéÖ¤BLDMÄ£×Ó£©£ºÊ¹Óûúеѧϰ¾ÙÐÐÄ£×ÓÌØÕ÷ɸѡºÍÄ£×Ó¹¹½¨¡£¸ÃÄ£×ÓÔÚ°üÀ¨55ÃûÁ¼ÐÔ½á½ÚºÍ42Ãû¶ñÐÔ½á½Ú»¼ÕßµÄÐÐÁÐÖоÙÐÐÁËÑéÖ¤¡£
µÚ¢ó½×¶Î£¨BLDMÄ£×ӵIJâÊÔ£©£ºÒ»Ö§°üÀ¨53ÃûÁ¼ÐÔ½á½ÚºÍ35Ãû¶ñÐÔ½á½ÚÐÐÁÐ×ÔÁ¦ÐÐÁÐÓÃÓÚµ¥Ã¤Ä£×Ó²âÊÔ£¬ÑéÖ¤BLDMÄ£×ÓÇø·ÖÁ¼ÐÔ½á½ÚºÍ¶ñÐÔ½á½ÚµÄÄÜÁ¦¡£»ùÓÚ¸ÃÄ£×Ó£¬ÎÒÃÇÌá³öÁ˼××´ÏÙ½á½ÚÕï¶ÏºÍÖÎÁÆ·ÖÁ÷Á÷³Ì¡£
ͼ1 Ñо¿Éè¼Æ
¡¸Ö÷ÒªÑо¿Ð§¹û¡¹
1. BLDMÄ£×Ӿ߱¸ÅбðÕï¶Ï¼××´ÏÙ½á½ÚÁ¼¶ñÐÔµÄÄÜÁ¦£¬Ìá¸ßÁËACR TI-RADS ≥4Àà½á½ÚÕï¶ÏµÄ׼ȷÂÊ¡£
ÔÚµÚÒ»½×¶Î£¬ÎÒÃǹ²É¸Ñ¡³ö3184¸ö²î±ð»¯MHB¡£½øÒ»²½Ï¸»¯±ê¼Çºó£¬×îÖÕÑ¡Ôñ³ö60¸öMHB±ê¼ÇÀ´¹¹½¨BLDMÄ£×Ó£¬ÓÃÓÚÕï¶Ï¼××´ÏÙ½á½Ú¡£ÔÚѵÁ·¼¯ÖУ¬BLDMÄ£×Óƽ¾ùAUCΪ0.930±0.064£¨Í¼2A£©£¬¸ÃÕï¶ÏÄ£×ÓÔÚÑéÖ¤¼¯ÖеÄAUCΪ0.85£¨95%CI 0.820–0.902£©(ͼ2B)£¬ÆäÌØÒì¶ÈÏÔÖø¸ßÓÚ³¬Éù£¨90.91% vs. 43.64%£©¡£ÔÚ×ÔÁ¦²âÊÔ¼¯ÖУ¬BLDMµÄAUCΪ0.863£¨95%CI 0.837–0.900£©(ͼ2B)£¬ÆäÌØÒì¶ÈΪ88.68%(ͼ2D)¡£BLDMÄ£×ÓµÄÑôÐÔÕ¹ÍûÖµ£¨positive predictive value, PPV£©ÓÅÓÚ³¬Éù(ͼ2E)¡£Ê¹ÓÃBLDMÄ£×Ó£¬¶ÔACR TI-RADS 4ºÍACR TI-RADS 5Àà½á½ÚµÄÕï¶Ï׼ȷÂÊÌá¸ßÖÁ89.83%£¨Í¼2F£©¡£
ͼ2 BLDMÄ£×ÓµÄÐÔÄÜÑéÖ¤
2.BLDMÄ£×ÓÔÚ·ÇϸС½á½ÚºÍϸС½á½ÚÖеÄÐÔÄܽÔÓÅÓÚ³¬Éù
ÔÚ·ÇϸС½á½ÚµÄÕï¶ÏÖУ¬BLDMÏà½ÏÓÚ³¬Éù¾ßÓиü¸ßµÄÌØÒì¶ÈºÍ׼ȷ¶È £¨ÌØÒì¶È£º90.00%vs.57.50%£»×¼È·¶È£º86.96% vs. 60.87%£©£¨Í¼3A-C£©¡£±ðµÄ£¬BLDMÄ£×ÓÄÜÓÐÓÃÇø·Ö¼××´ÏÙϸСÈéÍ·×´°©(papillary thyroid microcarcinoma£¬PTMC)ºÍÁ¼ÐÔϸС½á½Ú£¨≤10mm£©£¬Æä׿ԽµÄÐÔÄÜÌåÏÖÔÚÆäÌØÒì¶ÈºÍ׼ȷ¶È»®·ÖΪ93.33%ºÍ88.24%£¨Í¼3D-F£©¡£BLDMÄ£×ÓÔÚϸС½á½ÚÖÐÌåÏÖ³ö¸ü¸ßµÄѸËٶȡ¢ÌØÒì¶È¡¢×¼È·¶ÈºÍ PPV¡£
ͼ3 BLDMÄ£×Ó¶Ô·ÇϸС½á½ÚºÍϸС½á½ÚµÄÕï¶ÏÐÔÄÜ
3.BLDMÄ£×ÓÔÚ¼××´ÏÙ½á½ÚÕï¶ÏºÍÖÎÁÆÖеÄÓ¦ÓÃ
»ùÓÚBLDMÄ£×Ó£¬ÎÒÃǽ¨ÒéACR TI-RADS 4-5ÀàµÄ»¼Õß¾ÙÐÐѪҺ²âÊÔ¡£ÈçBLDMÕ¹ÍûЧ¹ûΪ¶ñÐÔ½á½Ú£¬Ôò½¨Ò黼Õß¾ÙÐÐϸ°ûѧ¼ì²é£¨Í¼4£©¡£³¬ÉùÍŽáѪҺBLDMÄ£×ÓÓÐÖúÓÚ×èÖ¹²»ÐëÒªµÄ»î¼ì£¬²¢Îª¼××´ÏÙ»¼ÕßÌṩ¸üºÏÀí¡¢¸ü¸ßЧµÄÖÎÁƼƻ®¡£
ͼ4 »¼Õß¼ì²éºÍÖÎÁÆÁ÷³Ìͼ
¡¸Ð¡½á¡¹
ºã¾ÃÒÔÀ´£¬°©Ö¢µÄÕï¶ÏÒ»Ö±ÃæÁÙÌôÕ½£¬Ö»¹ÜACR TI-RADSÌá¸ßÁ˼××´ÏÙ½á½ÚÕï¶ÏµÄ׼ȷÐÔ£¬µ«Ðí¶à»¼ÕßÈÔ¾ÙÐÐÁ˲»ÐëÒªµÄ»î¼ì£¬Ö÷ÒªÊÇÓÉÓÚACR TI-RADS 4ºÍ5ÀàµÄÌØÒìÐÔÏà¶Ô½ÏµÍ¡£ÑªÒº°×ϸ°û²ÉÑùÀû±ã£¬¼ì²â±ã½Ý£¬ÎÒÃÇ¿ª·¢µÄ»ùÓÚÍâÖÜѪ°×ϸ°ûDNA¼×»ù»¯µÄÁ¢ÒìÒªÁìÀ´ÅбðÕï¶Ï¼××´ÏÙ½á½Ú£¬ÓëACR TI-RADSÏà±È£¬ÌåÏÖ³öÓÅÔ½µÄÌØÒì¶ÈºÍ׼ȷ¶È£¬ÔÚACR TI-RADS 4ºÍACR TI-RADS 5ÖÐÓÈÆäÏÔÖø¡£BLDMÄ£×ÓÄÜÓÐÓõØʶ±ð³¬ÉùÏÓÒÉΪ¼××´ÏÙ°©µÄÁ¼ÐÔ½á½Ú£¬´Ó¶øïÔ̲»ÐëÒªµÄ»î¼ì¼ì²é¡£ca88Ñо¿Ö¼ÔÚ¸ÄÉÆÏÖÔÚÖйú¼××´ÏÙ½á½ÚÌ«¹ýÕïÁƵÄÎÊÌ⣬´Ùʹ¼××´ÏÙ½á½ÚÔ½·¢ºÏÀíºÍ¸ßЧµÄÕï¶ÏºÍÖÎÁÆ¡£
¡¸²Î¿¼ÎÄÏס¹
[1] Feihang Wang, Danyang Zhao, Wang-Yang Xu, Yiying Liu, Huiyi Sun, Shanshan Lu, Yuan Ji, Jingjing Jiang, Yi Chen, Qiye He, Chengxiang Gong, Rui Liu, Zhixi Su, Yi Dong, Zhiping Yan, Lingxiao Liu. Blood leukocytes as a non-invasive diagnostic tool for thyroid nodules: a prospective cohort study. BMC Med. 2024;22(1):147.
[2] Jiang H, Tian Y, Yan W, Kong Y, Wang H, Wang A, Dou J, Liang P, Mu Y. The prevalence of thyroid nodules and an analysis of related lifestyle factors in Beijing communities. Int J Environ Res Public Health. 2016;13(4):442.
[3] Wong R, Farrell SG, Grossmann M. Thyroid nodules: diagnosis and management. Med J Aust. 2018;209(2):92–8.
[4] Durante C, Grani G, Lamartina L, Filetti S, Mandel SJ, Cooper DS. The diagnosis and management of thyroid nodules: a review. JAMA. 2018;319(9):914–24.
[5] Tessler FN, Middleton WD, Grant EG, Hoang JK, Berland LL, Teefey SA, Cronan JJ, Beland MD, Desser TS, Frates MC, et al. ACR thyroid imag? ing, reporting and data system (TI-RADS): white paper of the ACR TI-RADS committee. J Am Coll Radiol. 2017;14(5):587–95.
[6] Pandya A, Caoili EM, Jawad-Makki F, Wasnik AP, Shankar PR, Bude R, Haymart MR, Davenport MS. Retrospective cohort study of 1947 thyroid nodules: a comparison of the 2017 American College of Radiology TI-RADS and the 2015 American Thyroid Association Clas? sifcations. AJR Am J Roentgenol. 2020;214(4):900–6.
±¾ÎÄ°üÀ¨µÄËùÓÐÄÚÈݽö¹©×¨ÒµÈËÊ¿ÔĶÁ¼Î¿½å¼£¬·Ç¹ã¸æÓÃ;¡£